ES2187667T3 - Uso de relaxina para estimular angiogenesis. - Google Patents

Uso de relaxina para estimular angiogenesis.

Info

Publication number
ES2187667T3
ES2187667T3 ES96928212T ES96928212T ES2187667T3 ES 2187667 T3 ES2187667 T3 ES 2187667T3 ES 96928212 T ES96928212 T ES 96928212T ES 96928212 T ES96928212 T ES 96928212T ES 2187667 T3 ES2187667 T3 ES 2187667T3
Authority
ES
Spain
Prior art keywords
relaxin
stimulate angiogenesis
angiogenesis
infections
lack
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96928212T
Other languages
English (en)
Inventor
Elaine Unemori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Connetics Corp
Original Assignee
Connetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connetics Corp filed Critical Connetics Corp
Application granted granted Critical
Publication of ES2187667T3 publication Critical patent/ES2187667T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA RELAXINA ES UTIL PARA PROMOVER LA ANGIOGENESIS Y EL TRATAMIENTO DE INFECCIONES DE HERIDAS ISQUEMICAS EN LAS QUE LA LESION TIENE COMO RESULTADO LA FALTA DE OXIGENO DEBIDO A UNA MALA CIRCULACION.
ES96928212T 1995-08-15 1996-08-15 Uso de relaxina para estimular angiogenesis. Expired - Lifetime ES2187667T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US235595P 1995-08-15 1995-08-15

Publications (1)

Publication Number Publication Date
ES2187667T3 true ES2187667T3 (es) 2003-06-16

Family

ID=21700396

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96928212T Expired - Lifetime ES2187667T3 (es) 1995-08-15 1996-08-15 Uso de relaxina para estimular angiogenesis.

Country Status (9)

Country Link
US (3) US6211147B1 (es)
EP (1) EP0845992B1 (es)
JP (1) JP4568383B2 (es)
AT (1) ATE228004T1 (es)
AU (1) AU6777196A (es)
CA (1) CA2229479C (es)
DE (1) DE69624925T2 (es)
ES (1) ES2187667T3 (es)
WO (1) WO1997006814A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE362770T1 (de) * 2000-02-09 2007-06-15 Bas Medical Inc Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1765149B1 (en) * 2004-03-19 2016-09-28 University Of Pittsburgh Use of relaxin to increase arterial compliance
WO2005115435A2 (en) 2004-04-30 2005-12-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
US20060281669A1 (en) * 2005-06-13 2006-12-14 Yue Samuel K Method and compositions for the treatment of diabetes and related complications
US8496446B2 (en) * 2005-08-29 2013-07-30 Carrier Corporation Compressor muffler
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
AU2009246333B2 (en) * 2008-05-16 2013-05-09 Corthera, Inc. Method of promoting wound healing
CN102026650A (zh) * 2008-05-16 2011-04-20 科尔泰拉公司 预防早产的方法
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
EP2326667A4 (en) * 2008-09-05 2012-08-15 Univ Rio De Janeiro PROTEINIC ACID POLYMER, METHOD OF MANUFACTURE, USE OF PROTEINIC POLYMER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
US8758323B2 (en) 2009-07-30 2014-06-24 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
WO2013033324A2 (en) * 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9526762B1 (en) * 2013-08-09 2016-12-27 William Marsh Rice University Multidomain peptides for promoting angiogenesis
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) * 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
WO1989007945A1 (en) * 1988-02-26 1989-09-08 Genentech, Inc. Human relaxin formulation
GB8907799D0 (en) * 1989-04-06 1989-05-17 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
CA2051375C (en) 1989-05-04 2000-09-12 Dennis J. Henner Process and compositions for the isolation of human relaxin
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
CA2145515A1 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5911997A (en) * 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
US5753623A (en) * 1995-06-07 1998-05-19 Connetics Corporation Method of treatment for depression

Also Published As

Publication number Publication date
AU6777196A (en) 1997-03-12
WO1997006814A1 (en) 1997-02-27
EP0845992A1 (en) 1998-06-10
ATE228004T1 (de) 2002-12-15
CA2229479C (en) 2010-03-30
EP0845992A4 (en) 2000-04-19
US20010018418A1 (en) 2001-08-30
JPH11511174A (ja) 1999-09-28
US20040192606A1 (en) 2004-09-30
DE69624925D1 (de) 2003-01-02
DE69624925T2 (de) 2003-09-04
US6780836B2 (en) 2004-08-24
EP0845992B1 (en) 2002-11-20
CA2229479A1 (en) 1997-02-27
US6211147B1 (en) 2001-04-03
JP4568383B2 (ja) 2010-10-27

Similar Documents

Publication Publication Date Title
ATE228004T1 (de) Verwendung von relaxin zur stimulierung der angiogenese
BG98902A (bg) Имидазолови производни и тяхната употреба като инхибитори на цитокин
FI953717L (fi) 4-Hydroksibentsopyran-2-oneja ja 4-hydroksisykloalkyyli(b)pyran-2-oneja, joita voidaan käyttää retrovirusinfektioiden hoitamiseen
FI910413A7 (fi) Tooppiset valmisteet ihmisen kynsien hoitamiseksi
ATE111735T1 (de) Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen.
ID21948A (id) Penggunaan 1-hidroksi-2piridon untuk pengobatan infeksi-infeksi kulit
ATE235245T1 (de) Pharmaceutische komposition
ES2134184T3 (es) Empleo de etisterona para el tratamiento topico del acne o de la alopecia androgenetica.
ID21874A (id) Penggunaan 1-hidroksi-2-piridon untuk pengobatan infeksi urap kulit
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
BR9509925A (pt) Composição e uso da composição para prevenção ou tratamento de infecção por hiv-1
DK325387A (da) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid samt dets fremstilling og anvendelse
ATE109978T1 (de) Verwendung von purpuromycin zur behandlung von vaginalinfektionen.
ITTO930024A0 (it) Composizione per accelerare la rimarginazione di ferite
ITMI912466A1 (it) Uso di 1, 2 dipalmitoil-l-alfa-fosfatidil-n, n-dimetiletanolammina, in composizioni dermatologiche
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
BR9812489A (pt) Uso de 6,7-substituìdas-2-aminotetralinas adequadas para a preparação de uma composição farmacêutica para o tratamento terapêutico de patologias inflamatórias e/ou autoimunes
FI941707L (fi) Naftokinoninen käyttö P. carinii -infektioiden hoitoon ja profylaksiaan
ES555245A0 (es) Perfeccionamientos en aparatos para el tratamiento humedo de tejidos
FR2584605B1 (fr) Application du n-(1-allyl-2-pyrrolidinylmethyl) 2-methoxy 4-amino 5-methylsulfamoyl benzamide dans le traitement de la maladie de parkinson
IT8622024V0 (it) Tampone preconfezionato e sterilizzato per la medicazione di ferite relativamente grandi.
IT1274015B (it) Uso del ceruletide (takus) nel trattamento della psoriasi
ITMI920333A1 (it) Uso di sostanze parasimpaticomimetiche dirette per la terapia del dolore.
NO981020L (no) Transdermalt terapautisk system for silatranforbindelser